Cardio Diagnostics Holdings (NASDAQ: CDIO) is addressing the leading cause of death in the United States with a suite of artificial intelligence-powered solutions designed to improve cardiovascular disease prevention, detection, and management. The company announced its broad portfolio of clinical, population health, and biopharma tools, which integrate AI, epigenetics, and genetics to identify risk earlier and guide personalized interventions.
Cardiovascular disease remains the top killer in the U.S., but an estimated 80% of cases are considered preventable through earlier detection and proactive risk factor management. This statistic underscores the urgent need for more effective tools that can identify risk before symptoms appear. Cardio Diagnostics’ platform aims to fill that gap by offering blood-based testing that combines genetic and epigenetic biomarkers with AI-driven analytics to provide personalized cardiovascular insights.
The company currently offers two clinical solutions: Epi+Gen CHD and PrecisionCHD. These tools are part of a strategy that addresses cardiovascular disease across multiple stages of care, from prevention to management. The emphasis on prevention aligns with a growing recognition that earlier intervention can significantly improve long-term outcomes.
Cardio Diagnostics’ approach reflects a shift toward proactive healthcare, leveraging advanced technologies to move beyond traditional risk assessment methods. By integrating AI with epigenetic and genetic data, the company aims to provide more precise risk stratification and enable tailored prevention strategies for individuals.
The announcement comes amid increasing focus on preventive medicine and the role of AI in healthcare. With cardiovascular disease costing the U.S. healthcare system billions annually, tools that can reduce the burden through early detection could have significant public health and economic implications.
For more information, the full terms of use and disclaimers are available on the InvestorBrandNetwork website at http://IBN.fm/Disclaimer. The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO.
Forward-looking statements in this article are based on current expectations and involve risks and uncertainties. These include factors described in the company’s filings with the SEC, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Cardio Diagnostics undertakes no duty to update this information unless required by law.
